Join the Gastric Cancer group to help and get support from people like you.
Gastric Cancer News
H. Pylori Testing Feasible for People in Community Settings
THURSDAY, April 18, 2024 – Community Helicobacter pylori (HP) testing in high-risk individuals is technically feasible, according to a study published online April 3 in Clinical Gastroenterology and ...
Today's Young Adults Are Aging Faster, and That Might Help Spur Cancers
MONDAY, April 8, 2024 – Younger generations are aging more rapidly, and this could be leading to an increased risk of cancer, a new study says. People born in or after 1965 are 17% more likely to be...
AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
MONDAY, April 8, 2024 – For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free...
Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
MONDAY, Feb. 12, 2024 – For patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who experienced disease progression on first-line chemotherapy, fruquintinib (F) plus...
Country Music Star Toby Keith Dies of Cancer at 62
TUESDAY, Feb. 6, 2024 – Country singer Toby Keith, best known for chart-topping hits like "Who’s Your Daddy?” and “Made in America," has died at 62 from stomach cancer. His death was announced on his...
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
FRIDAY, Dec. 22, 2023 – Higher ultra-processed food (UPF) consumption is associated with a greater risk for head and neck cancer (HNC) and esophageal adenocarcinoma (OAC), according to a study...
ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
WEDNESDAY, Oct. 25, 2023 – For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and...
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
FRIDAY, Sept. 1, 2023 – For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ)...
K-ECAN Tool Can Predict Esophageal, Gastric Cardia Adenocarcinoma
MONDAY, Aug. 28, 2023 – The Kettles Esophageal and Cardia Adenocarcinoma predictioN (K-ECAN) Tool can predict incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) using...
2010 to 2019 Saw Increase in Incidence of Early-Onset Cancers in U.S.
FRIDAY, Aug. 18, 2023 – From 2010 to 2019, the incidence rates of early-onset cancers increased, with gastrointestinal cancers having the fastest-growing incidence rates, according to a study...
Antibody Treatment Zanidatamab Could Fight Rare But Deadly Bile Duct Cancers
MONDAY, June 12, 2023 – Patients with bile duct cancer might soon have an additional treatment available to them, thanks to a newly discovered tumor target. Some bile duct cancers are driven by a...
More Evidence That Obesity Raises Odds for Gastrointestinal Cancers
FRIDAY, May 12, 2023 – Maintaining a healthy weight may be important for reducing the risk of gastrointestinal cancer, a new study suggests. The research adds to the evidence that excess weight and...
Overweight, Obesity in Early, Middle Adulthood Increases Risk for GI Cancers
THURSDAY, May 11, 2023 – Overweight and obese body mass indices (BMIs) in early and middle adulthood are associated with a higher risk for colorectal cancer (CRC) and non-CRC gastrointestinal (GI)...
FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial ...
FDA Approves Merck’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Ask a question
To post your own question to this support group, sign in or create an account.